According to Zhitong Finance App News, Heyuan Biotech (688765.SH) disclosed its report for the third quarter of 2026. In the first three quarters, the company achieved operating income of 27.83 million yuan, an increase of 41.55% over the previous year; a net profit loss of 106 million yuan to mother after deducting a loss of 136 million yuan in non-net profit; and basic earnings per share - 0.30 yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.